Trial Profile
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs Mazdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Jun 2022 Results from NCT03325387 and NCT03928379 analyzing whether LY3305677 improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes, presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.